Advanced Ovarian Cancer and PARP Inhibitors: Clinical Insights and Impact on New Data

Access Activity

Overview / Abstract:

In this CME activity, Susana M. Campos, MD, MS, MPH, reviews some of the recent clinical developments in the treatment of patients with advanced ovarian cancer with PARP inhibitors. We welcome you to learn more about the updated data from key clinical studies of PARP inhibitor maintenance therapy in advanced ovarian cancer, and the implications of the results on the current and emerging concepts in ovarian cancer clinical practice.
• Platinum-sensitive recurrent ovarian cancer
• Advanced ovarian cancer with BRCA mutation
• PARP inhibitor maintenance therapy
• Patient-reported outcomes
• Individualized PARP inhibitor dosing
• Long-term safety and tolerability


Sep 30, 2022


Nurse Practitioner , Physician CME


Webinar / Webcast / Video

Credits / Hours

.50 credit hrs



Presenters / Authors / Faculty

Susana Campos, MD, MS, MPH
Assistant Professor, Medicine
Harvard Medical School
Boston, Massachusetts
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Gregory Scott, PharmD
WriteHealth, LLC
Kennebunk, Maine

Activity Specialities / Related Topics

OB/GYN / Women's Health, Oncology / Cancer / Radiation Therapy, Pathology, Radiology / Imagery / Nuclear Medicine

Sponsors / Supporters / Grant Providers

This educational activity is supported by an educational grant from GlaxoSmithKline.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Ovarian Cancer PARP Inhibitors Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map